

# The 12th Annual BioCity Symposium

## Recent BREAKTHROUGHS in drug development

22-23 August 2002, Mauno Koivisto Centre, BioCity, Turku

### Thursday, August 22

#### Session I: Inflammatory diseases

(Chair Riitta Lahesmaa)

- 9.30** Opening (**Mark Johnson**)  
**9.45** **Larry Steinman**, Beckman Center for Molecular Medicine, Stanford University  
**10.30** **Garrison Fathman**, Stanford University: Autoimmune diseases: from genes, bugs and failed regulation to better therapeutics  
**11.15** *Poster Session A, Coffee, Tea & Exhibition*  
**12.00** **Doreen Ann Cantrell**, Lymphocyte Activation Laboratory, Imperial Cancer Research Fund, London: Signal transduction and T cell biology  
**12.45** *Lunch & Exhibition*

#### Session II: Molecular targeting in cancer treatment

(Chair Pirkko Härkönen)

- 13.45** **Dario D. R. Alessi**, MRC Protein Phosphorylation Unit, School of Life Sciences, Division of Cell Signalling, University of Dundee: Structural and Functional Analysis of PDK1  
**14.30** **Olli Kallioniemi**, Medical Biotechnology Group, VTT-Turku and University of Turku: Biochips in cancer target identification and validation  
**15.15** *Coffee, Tea & Exhibition*  
**16.00-** **Karl-Heinz Thierauch**, Experimental Oncology,  
**16.45** Schering AG, Berlin: The profile of PTK787/ZK222584, a novel and orally active angiogenesis inhibitor, discovered by concept-based search  
**19.00** *Symposium Party*

### Friday, August 23

#### Session III: Novel therapeutics from bench to bedside

(Chair Olli Lassila)

- 9.30** **Freddy Radtke**, Ludwig Institute for Cancer Research (LICR), Switzerland: The role of Notch1 during T cell development and skin homeostasi  
**10.15** **Sirpa Jalkanen**, MediCity Research Laboratory, University of Turku: Homing-associated molecules as targets of drug development  
**11.00** *Poster Session A, Coffee, Tea & Exhibition*  
**12.00** **Stefan Hemmerich**, Thios Biotechnology, Oakland, USA: Carbohydrate sulfotransferases: novel therapeutic targets for inflammation viral infection and cancer  
**12.45** *Lunch & Exhibition*

#### Session IV: Antiviral therapy

(Chair Veijo Hukkanen)

- 13.45** **Bernard Roizman**, Departments of Molecular Genetics and Cell Biology, and Molecular Biology, University of Chicago: Novel targets for Anti Herpes Simplex Virus Therapy  
**14.30** **Richard J. Whitley**, Department of Pediatrics, University of Alabama at Birmingham: Current status of therapy of herpesvirus infections: hopes and shortcomings  
**15.15** *Coffee, Tea & Exhibition*  
**15.45** **Frederick G. Hayden**, University of Virginia: Advances in Anti-rhinovirus Therapy  
**16.30-** *Closing remarks and poster prizes*  
**16.45**



UNIVERSITY  
OF TURKU



ÅBO AKADEMI  
UNIVERSITY

#### Organised by:

BioCity Turku  
University of Turku  
Åbo Akademi University

#### Registration & information:

BioCity Turku, POB 123,  
FIN-20521 Turku.  
Tel +358 2 333 8042 or  
+358 50 577 4803

#### Invitation to poster session:

Participants are invited to present their results in poster format. Deadline for submission of poster abstracts (one A4) is August 7, 2002, and they should be sent to [biocity@turku.fi](mailto:biocity@turku.fi). The presenting author should be underlined. Poster size is 84 cm wide and 116 cm high.



BIOTURKU